Investment in R&D

CSL is investing in the development of new protein-based medicines for treating serious human diseases as an important avenue to future growth. We have increased our investments significantly over recent years. In 2014/15 we invested US$463 million in our R&D programs.

We now have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in life cycle management and market development of existing products that bring short to mid-term commercial benefits, as well as strategic investments in longer term, higher risk and high opportunity new product development activities in areas aligned with our core capabilities and commercial strengths.
  Vreni Fortsch, Manager Process Development in Bern, filtering a plasma fraction.

CSL Research and Development Investment (US$ Millions)

R&D Investment 2015-2016

© 2017 CSL Limited